iCAD Congratulates Accuray on Winning ‘Best New Radiology Device 2010’ for its CyberKnife VSI System

NASHUA, N.H.--(BUSINESS WIRE)-- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, congratulates its partner, Accuray, in receiving a 2010 Minnie Award for the CyberKnife® VSI System. The Minnie Awards are an annual event produced by AuntMinnie.com, a highly-regarded news and research outlet for radiologists and related professionals in the medical imaging industry.

The CyberKnife VSI System extends the CyberKnife System’s world-class, robotic radiosurgery capabilities to enable high precision radiation therapy and Robotic IMRT™. The CyberKnife System is a non-invasive alternative to surgery for the treatment of both cancerous and non-cancerous tumors anywhere in the body where radiation is indicated, and is frequently used to treat patients with early-stage prostate cancer.

“We are pleased to congratulate Accuray for its Minnie Award,” said Rick Ortega, Director of MRI Programs at iCAD. “iCAD has worked closely with Accuray to help physicians better diagnose and treat prostate cancer, which can be a challenge because of the vascularity and its location deep within the abdominal/pelvic cavity. This award recognizes Accuray for its technological breakthrough in delivering potentially lifesaving radiation therapy, non-invasively, for cancer patients.”

iCAD will be hosting several mini educational sessions at its booth, #6216, at the 2010 RSNA meeting, being held in Chicago from November 28 to December 3, 2010. One of the sessions, “Treatment Planning with the CyberKnife® Robotic Radiosurgery System and Quantitative Image Analysis,” will provide insight on how DCE MRI with iCAD’s quantitative image analysis solution, VividLook®, can improve the sensitivity and specificity of prostate cancer localization, detection and improved treatment planning for patients undergoing CyberKnife therapy. These sessions are scheduled for:

  • Monday, November 29, from 2:30 to 2:45 PM
  • Tuesday, November 30, from 4:30 to 4:45 PM

More information on the educational sessions can be found at www.icadmed.com/newsevents/RSNA2010.htm.

“The CyberKnife radiosurgical planning and delivery system can be used to create an extremely customized radiation dose distribution tailored to focus the highest regions of dose on the most heavily cancer involved areas within the prostate and deliver this dose pattern with sub-millimeter accuracy and precision,” said Donald B. Fuller, M.D., radiation oncologist, the CyberKnife Centers of San Diego and Radiation Medical Group. “The iCAD VividLook technology represents an innovative next-generation imaging method for mapping these tumor-bearing regions, exceeding the capability of existing diagnostic techniques. The direct three-dimensional computerized integration of these complementary technologies shows great promise in delivering a quantum leap forward in the customization of every treatment plan, to most exactly and safely treat the specific cancer involvement pattern of each individual prostate cancer patient.”

More information on the Minnie Award can be found by visiting:

http://www.auntminnie.com/index.asp?Sec=nws&sub=rad&pag=dis&ItemId=92410

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 100,000 patients worldwide and currently more than 215 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography and computed radiography), Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). Since receiving FDA approval for the Company’s first breast cancer detection product in 2002, more than 4,000 iCAD systems have been placed in healthcare practices worldwide. iCAD’s solutions aid in the early detection of the most prevalent cancers including breast, prostate, colon, and in the future, lung cancer. For more information, call (877) iCADnow or visit www.icadmed.com.

**NOTE TO EDITORS, IMAGES AVAILABLE

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.



CONTACT:

For iCAD
Darlene Deptula-Hicks, 603-882-5200 x7944
[email protected]
or
For Investor Relations
Lippert/Heilshorn & Associates
Anne Marie Fields, 212-838-3777 x6604
[email protected]
or
For media inquiries
MS&L PR
Liza Heapes, 617-369-8787
[email protected]

KEYWORDS:   United States  North America  New Hampshire

INDUSTRY KEYWORDS:   Technology  Data Management  Software  Health  Hospitals  Medical Devices  Radiology  Other Health

MEDIA:

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.